CRBU Caribou Biosciences, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1619856 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.6%
TTM net income YoY34.8%
TTM EPS YoY39.4%
Revenue 3-yr CAGR-35.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,140.6%
Net margin-1,085.0%
FCF margin-984.6%
EBITDA margin-1,113.6%
Returns
ROE-93.8%
ROA-64.4%
ROIC (approx.)-93.9%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets37.7%
Debt / equity0.00x
Current ratio4.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue-1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.61M | $1.50M | $2.40M | $3.94M | $2.20M | $2.67M | $2.35M | $2.08M |
| R&D expense | $21.35M | $18.94M | $20.61M | $23.82M | $22.40M | $27.69M | $35.53M | $30.46M |
| SG&A expense | $7.90M | $7.90M | $8.07M | $8.58M | $9.20M | $10.40M | $9.73M | $10.49M |
| Operating income | -$27.64M | -$25.34M | -$26.28M | -$28.45M | -$29.40M | -$47.58M | -$42.91M | -$38.88M |
| Income tax | — | — | $0 | -$550,000 | $0 | — | $0 | -$9,000 |
| Net income | -$26.61M | -$24.28M | -$25.09M | -$26.49M | -$27.55M | -$54.10M | -$39.99M | -$35.49M |
| EBITDA | -$27.05M | -$24.71M | -$25.63M | -$27.77M | -$28.77M | -$46.41M | -$41.75M | -$37.69M |
| EPS (basic) | -0.25 | -0.24 | -0.26 | — | -0.30 | -0.58 | -0.43 | — |
| EPS (diluted) | -0.25 | -0.24 | -0.26 | — | -0.30 | -0.58 | -0.43 | — |
| Weighted avg. shares (diluted) | 107.54M | 100.99M | 95.86M | — | 93.29M | 93.03M | 92.68M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $26.06M | $26.19M | $12.06M | $12.36M | $11.14M | $25.20M | $29.42M | $16.34M |
| Short-term investments | $68.74M | $86.12M | $105.57M | $126.98M | $136.12M | $158.75M | $179.05M | $193.24M |
| Receivables | $518,000 | $203,000 | $227,000 | $69,000 | $242,000 | $71,000 | $88,000 | $265,000 |
| Current assets | $100.08M | $116.59M | $122.38M | $145.23M | $155.51M | $192.51M | $217.32M | $219.38M |
| PP&E, net | $4.87M | $5.50M | $6.12M | $6.76M | $7.60M | $8.18M | $18.52M | $19.28M |
| Total assets | $123.03M | $142.77M | $149.00M | $175.37M | $194.98M | $220.90M | $273.66M | $313.31M |
| Current liabilities | $20.14M | $17.97M | $19.67M | $25.41M | $28.06M | $28.89M | $28.49M | $30.65M |
| Total liabilities | $46.39M | $44.67M | $46.98M | $53.19M | $53.14M | $54.77M | $56.43M | $60.36M |
| Shareholders' equity | $76.63M | $98.10M | $102.02M | $122.17M | $141.84M | $166.13M | $217.22M | $252.95M |
| Shares outstanding | 108.04M | 106.00M | 96.95M | 95.14M | 93.47M | 93.12M | 93.00M | 92.38M |
| Cash flow statement | ||||||||
| Operating cash flow | -$22.52M | -$22.79M | -$26.98M | -$20.82M | -$25.18M | -$28.26M | -$36.73M | -$35.47M |
| Capital expenditure | $19,000 | $1,000 | $72,000 | -$216,000 | $115,000 | $418,000 | $1.04M | $518,000 |
| Free cash flow | -$22.54M | -$22.79M | -$27.06M | -$20.61M | -$25.30M | -$28.68M | -$37.77M | -$35.99M |
| Investing cash flow | $19.39M | $18.94M | $23.98M | $17.97M | $10.85M | $24.04M | $49.38M | $15.93M |
| Financing cash flow | $2.99M | $17.94M | $2.70M | $4.07M | $277,000 | $6,000 | $468,000 | $3.86M |
| Depreciation & amortization | $590,000 | $625,000 | $649,000 | $682,000 | $631,000 | $1.17M | $1.17M | $1.18M |
| Stock-based compensation | $2.16M | $2.48M | $2.36M | $2.74M | $2.93M | $3.13M | $3.88M | $3.91M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.